Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000394419 | SCV000330281 | pathogenic | not provided | 2023-07-31 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26860062, 26520804) |
Institute of Medical Genetics and Applied Genomics, |
RCV003236667 | SCV003935184 | pathogenic | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1 | 2023-06-26 | criteria provided, single submitter | clinical testing | |
Rady Children's Institute for Genomic Medicine, |
RCV005250045 | SCV005900708 | pathogenic | PIK3R2-related disorder | 2023-12-26 | criteria provided, single submitter | clinical testing | The c.1126A>G (p.Lys376Glu) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. This variant has been previously reported as a heterozygous change in patients with polymicrogyria (PMID: 26520804, 33057194, 37486637). The c.1126A>G (p.Lys376Glu) variant is located in the SH2 domain, which is a known hotspot domain for pathogenic variations associated with polymicrogyria (PMID: 26520804). The c.1126A>G (p.Lys376Glu) variant is absent from the gnomAD population database and thus is presumed to be rare. Based on the available evidence, c.1126A>G (p.Lys376Glu) is classified as Pathogenic. |
Yale Center for Mendelian Genomics, |
RCV001849360 | SCV002106993 | pathogenic | Seizure | 2021-04-05 | no assertion criteria provided | literature only |